Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer

Sorafenib and sunitinib are multiple tyrosine kinase inhibitors. Both of them have been approved by the US FDA in the treatment of patients with malignancies. In order to develop an effective and clinically useful chemoimmunotherapy modality against hepatocellular cancer (HCC), we investigate their...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Dai, Qi, Xiaoqiang, Manjunath, Yariswamy, Kimchi, Eric T., Ma, Lixin, Kaifi, Jussuf T., Staveley-O’Carroll, Kevin F., Li, Guangfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093187/
https://www.ncbi.nlm.nih.gov/pubmed/30123861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093187/
https://www.ncbi.nlm.nih.gov/pubmed/30123861

Ejemplares similares